Allergan plc (NYSE: AGN), formally known as Actavis plc, is a pharmaceutical company that develops, manufactures, markets and distributes generic, brand and over-the-counter products. Its four business segments are U.S. brands, U.S. medical aesthetics, international brands and Abbreviated New Drug Application (ANDA) distribution. Allergan has a market capitalization of $56 billion as of January 2018.

Top Allergan direct shareholders in 2016 include the following individuals.

Paul Bisaro

Paul Bisaro was the executive chairman of Allergan and has held this position between July 2014 and October 2016. He served as Allergan’s chief executive officer (CEO) between September 2007 and July 2014. Bisaro was the top direct Allergan shareholder as of December 2017, directly holding 265,253 shares. Before joining Allergan, Bisaro was president and chief operating officer (COO) at Barr Pharmaceuticals Inc. from 1999 to 2007. Earlier in his career, he held various roles at law firm, Winston & Strawn and accounting firm, Arthur Andersen LLP. He is also an independent director of Zimmer Biomet Holdings Inc. (NYSE: ZBH) and Forsyth Capital Mortgage Corp. His academic qualifications include a bachelor of general studies and Juris Doctor (JD) degree. 

Brenton Saunders

Brenton Saunders replaced Paul Bisaro as Allergan’s CEO in July 2014 and as chariman in October 2016. He is the company’s second-largest direct shareholder, with 177,631 shares as of December, 2017. Before taking the top job at Allergan, Saunders was CEO and president of Forest Laboratories Inc. for 12 months. He has extensive experience in the health care and pharmaceuticals industries, having held senior leadership positions at Schering-Plough, PricewaterhouseCoopers LLP and Home Care Corporation of America. He began his career as a compliance officer with the Thomas Jefferson University Health System. Saunders holds a master of business administration (MBA) from Temple University School of Business. He additionally has a JD degree.

Robert Stewart

Robert Stewart serves as the company's executive vice-president and chief operating officer. He has been in his current role since May 2016, prior to which he headed the Allergan's generics and global operations business. With direct ownership of 66,650 shares as of December 2017, Stewart is the company's third-largest shareholder. He is a 20 year year veteran in the global pharamceuticals business with previous work experience with companies like Abbott Laboratories, Knoll Pharmaceuticals and Hoffman La-Roche Inc.

William Meury

William Meury has been the chief commercial officer of Allergan since May 2016; he previously served as the company’s executive vice president between March 2015 and May 2016. Meury held 55,410 shares directly as of December 2017, making him Allergan’s fourth-largest direct shareholder. Meury gained valuable industry experience, overseeing several departments at Forest Laboratories Inc. from 1993 to 2013. He spent the early part of his career performing financial reporting for public accounting firm Reznick Fedder & Silverman, now CohnReznick LLP. He holds a bachelor of science in economics from the University of Maryland.

Karen Ling

Karen Ling is the the company's executive vice-president and chief human resources officer since July 2014. With direct ownership of 27,873 Ling is the fifth largest individual shareholder of the company. She has previously worked with Forrest Laboratories, Merck & Co. and Wyeth Pharmaceuticals.

Allergan’s five largest institutional shareholders include the Vanguard Group, holding 23.917 million shares; Wellington Management Company LLP, holding 19.6 million shares; Government of Singapore InvestCorp holding 16.9 million shares; State Street Corporation (NYSE: STT), holding 15.15 million shares and FMR LLC, holding 13.38 million shares. These five holdings represent roughly 26% of the company.


Want to learn how to invest?

Get a free 10 week email series that will teach you how to start investing.

Delivered twice a week, straight to your inbox.